A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
Latest Information Update: 29 Apr 2024
Price :
$35 *
At a glance
- Drugs CBT 006 (Primary)
- Indications Meibomianitis
- Focus Adverse reactions
- Sponsors Cloudbreak therapeutics
- 06 Jun 2022 Status changed from recruiting to completed.
- 28 Apr 2022 Planned primary completion date changed from 1 Mar 2022 to 10 May 2022.
- 20 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Sep 2022.